IDEXX Laboratories (NASDAQ:IDXX) Shares Acquired Rep. Jefferson Shreve

Representative Jefferson Shreve (R-Indiana) recently bought shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX). In a filing disclosed on April 11th, the Representative disclosed that they had bought between $15,001 and $50,000 in IDEXX Laboratories stock on March 13th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Harley-Davidson (NYSE:HOG) on 3/31/2025.
• Purchased $50,001 – $100,000 in shares of Block (NYSE:XYZ) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of DuPont de Nemours (NYSE:DD) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of United Community Banks (NASDAQ:UCB) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of IDEX (NYSE:IEX) on 3/31/2025.
• Purchased $15,001 – $50,000 in shares of HNI (NYSE:HNI) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of ServiceNow (NYSE:NOW) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Coinbase Global (NASDAQ:COIN) on 3/31/2025.
• Sold $15,001 – $50,000 in shares of Constellation Energy (NASDAQ:CEG) on 3/31/2025.
• Sold $50,001 – $100,000 in shares of Simon Property Group (NYSE:SPG) on 3/31/2025.

IDEXX Laboratories Stock Down 0.2 %

Shares of IDEXX Laboratories stock traded down $0.63 during midday trading on Tuesday, hitting $404.02. The company’s stock had a trading volume of 985,075 shares, compared to its average volume of 619,975. The firm has a market capitalization of $32.74 billion, a P/E ratio of 37.87, a PEG ratio of 3.41 and a beta of 1.50. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a 50-day simple moving average of $425.62 and a 200-day simple moving average of $432.65.

Hedge Funds Weigh In On IDEXX Laboratories

Institutional investors have recently bought and sold shares of the stock. Hurley Capital LLC bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at approximately $29,000. Rialto Wealth Management LLC acquired a new position in IDEXX Laboratories during the fourth quarter valued at approximately $30,000. Retirement Wealth Solutions LLC bought a new position in shares of IDEXX Laboratories in the fourth quarter valued at approximately $31,000. Colonial Trust Co SC lifted its stake in shares of IDEXX Laboratories by 84.8% in the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after buying an additional 39 shares during the last quarter. Finally, Kestra Investment Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $38,000. 87.84% of the stock is currently owned by institutional investors.

Insider Activity at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP George Fennell sold 9,986 shares of IDEXX Laboratories stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have weighed in on IDXX. Piper Sandler lifted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research report on Monday. Bank of America increased their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Barclays boosted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $523.75.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.